MOCOS
MOCOS (molybdenum cofactor sulfurase, also known as HMCS, MOS and MCS) is an enzyme that sulfurates the molybdenum cofactor. This step activates xanthine dehydrogenase and aldehyde oxidase, and loss of function causes classical xanthinuria type II. Browse Assay Genie's current range of MOCOS research reagents below, or read on for the biology behind the target.
MOCOS sulfurates the molybdenum cofactor. In xanthine dehydrogenase (XDH) and aldehyde oxidase (AO, also written ADO in UniProt), the molybdenum cofactor is active only when it is liganded by one oxygen and one sulfur atom, so sulfuration by MOCOS is essential for both enzymes. XDH catalyses the conversion of hypoxanthine to uric acid via xanthine. It also converts allopurinol to oxypurinol and pyrazinamide to 5-hydroxy pyrazinamide. In vitro, the C-terminal domain of the MOCOS protein can reduce N-hydroxylated prodrugs such as benzamidoxime.
The MOCOS gene encodes a protein that belongs to the class-V pyridoxal-phosphate-dependent aminotransferase family, MOCOS subfamily. HGNC places it in the molybdenum cofactor synthesis proteins gene group, and the enzyme carries the EC number 2.8.1.9. A mouse ortholog, Mocos, is recorded. Subcellular location is not annotated in UniProt, so the data supplied do not support a localisation claim.
Mutations in the MOCOS gene cause the metabolic disorder classical xanthinuria type II. The condition is characterised by loss of XDH/XO and AO enzyme activity and decreased uric acid in the urine. Xanthine and hypoxanthine are raised in serum and urine. Xanthine stones form in the urinary tract, and xanthine deposition in tissue causes myositis. Researchers studying MOCOS, whether through a MOCOS antibody, a MOCOS ELISA kit or other approaches, are usually interested in purine catabolism, cofactor biology and drug metabolism.
MOCOS activates XDH, which converts hypoxanthine to uric acid via xanthine, placing the enzyme at a key step of purine catabolism.
Mutations in the MOCOS gene cause classical xanthinuria type II, with xanthine stones, raised xanthine and hypoxanthine, and low urinary uric acid.
MOCOS sulfurates the molybdenum cofactor, giving the oxygen and sulfur ligation that XDH and aldehyde oxidase need to be active.
XDH converts allopurinol and pyrazinamide, and the MOCOS C-terminal domain can reduce N-hydroxylated prodrugs such as benzamidoxime in vitro.
MOCOS sulfurates the molybdenum cofactor. Sulfation of molybdenum is essential for xanthine dehydrogenase and aldehyde oxidase, in which the cofactor is liganded by one oxygen and one sulfur atom in its active form. Without MOCOS activity, both enzymes lose function.
MOCOS is the HGNC symbol for molybdenum cofactor sulfurase. Aliases and earlier symbols include HMCS, FLJ20733, MOS and MCS. The enzyme is classified as EC 2.8.1.9 and belongs to the class-V pyridoxal-phosphate-dependent aminotransferase family, MOCOS subfamily.
Yes. Mutations in the MOCOS gene cause classical xanthinuria type II. Affected people lack XDH/XO and AO activity, have low urinary uric acid, and have raised xanthine and hypoxanthine. They can form xanthine stones and develop myositis. A mouse ortholog, Mocos, exists; check the datasheet of any product for its validated reactivity.
Other molybdenum cofactor synthesis proteins, molybdenum-dependent enzymes and purine metabolism targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q96EN8; product specifications from Assay Genie datasheets.